ArticleEuropean journal of medicinal chemistry2025

The polypharmacy combination of the BCL-2 inhibitor venetoclax (VEN) and the FLT3 inhibitor gilteritinib (GIL) is more active in acute myeloid leukemia cells than novel polypharmacologic BCL-2/FLT3 VEN-GIL hybrid single-molecule inhibitors.

Christopher C Goodis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.